



2nd IGTP Retreat: Research and Networking across the Can Ruti Campus

14-15 June 2021

Objectives

The objectives of this meeting are to showcase ground-breaking research on the campus, highlight strategic projects and provide an area for reflection on the COVID-19 pandemic (what has happened and what will happen in the future).

Organizers

- Jordi Barretina, Director, IGTP
- Julia García-Prado, Scientific Director IGTP, Viral Immune Evasion and Vaccines Group (VIRIEVAC) IrsiCaixa

Scientific Committee

- Pere Clavé, Professor of Surgery, Director of Research and Academic Development at CSdM
- Mireia Margelí, Head of Unit and Coordinator of Functional Breast Unit, ICO-Badalona
- Gisela Nogales and Dr Mónica Suelves, Neuromuscular and Neuropaediatric Research Group, IGTP
- José A Domínguez, Innovation in Respiratory Infections and Tuberculosis Diagnosis Group, IGTP
-

Organizing Committee

- Harvey Evans, IGTP
- Meritxell Nevado, IGTP
- Roser Montserrat, IGTP



Programme

Day One

15.00 WELCOME & OPENING REMARKS FROM THE IGTP DIRECTORS

- **Jordi Barretina**, Director IGTP
- **Julia García-Prado**, Scientific Director IGTP

16.00 -17.00 Keynote speaker

A view of translational cancer research from 2021 onwards

Aleix Prat, Head Medical Oncology, Hospital Clínic of Barcelona
Translational Genomics and Targeted Therapies Group, IDIBAPS Professor,
University of Barcelona
Chair: **Jordi Barretina**

17.00 closure of day one

Day Two

9.30- 10.30 SESSION ONE - Personalized Medicine

Chair: **Mireia Margelí**

Strategic Projects

- Genomics and Translational Bioinformatics for Personalized Medicine of NF1-associated Tumors
Bernat Gel Moreno, IGTP
- SMA-TB project: A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy in TB patients
Cristina Vilaplana, IGTP



Young investigators' presentations

- Identification of a novel biomarker of resistance to platinum-based drugs through modification of DNA damage response
Lucía Gutiérrez Chamorro, IrsiCaixa
- Determinants of immunoevasion in MET driven lung cancer within the adenosinergic signature
Maria Saigí Morguí, ICO
- Pathologic involvement of the farnesoid X receptor/fibroblast growth factor 19 axis to the Crohn's disease early postsurgical recurrence
Roger Suau Regordosa, IGTP

10.30 - 11.30 SESSION TWO - Advanced Therapies and Innovation

Chair: **Pere Clavé**

Strategic Projects

- Extracellular vesicles from mesenchymal stromal cells combined with tissue engineering for myocardial repair
Marta Monguió Tortajada, IGTP
- Neurophysiological evaluation of swallow, the pathway to personalized oropharyngeal dysphagia management
Omar Ortega Fernández, CSdM

Young investigators' presentations

- Efficacy and safety of rTMS associated with rehabilitation for the improvement of upper extremity functionality in subacute phase stroke in the context of intensive neurorehabilitation. A pilot Study.
Nadia Sánchez Fernández, Guttman Institute
- Tolerogenic dendritic cell-based treatment in multiple sclerosis (MS): TOLERVIT-MS, a phase I clinical trial.
Silvia Presas Rodríguez, IGTP
- Myeloid-Derived Suppressor Cells in kidney and lung transplant recipients
Maria Iglesias Escurdero, HUGTiP



12.00 – 13.00 SESSION THREE ROUND TABLE DISCUSSION: How COVID-19 has changed our research and how it will continue to change it

Chair: **Julia García-Prado**

- Antoni Bayés-Genís, Head of Cardiology, Hospital Universitari Germans Trias i Pujol & IGTP
- Jordi Casabona, Director CEEISCAT, ICO, IGTP
- Clara Prats, Associate Professor, Polytechnic University of Catalonia (UPC), IGTP-CMCiB
- Elia Torroella, R&D and Regulatory Affairs Director, HIPRA

14.00 - 15.00 SESSION FOUR – Rare Diseases

Chair: **Mònica Suelves**

Strategic Projects

- Deciphering the Genetic Basis of Inherited Ataxias
Antoni Matilla Dueñas, IGTP
- Towards a precision medicine for childhood liver cancer
Carolina Armengol Niell, IGTP

Young investigators' presentations

- Establishment of an iPSC-derived human in vitro/in vivo human plexiform neurofibroma model
Helena Mazuelas Gallego, IGTP
- DNA methylation profiles across clinical subtypes of Myotonic Dystrophy type 1 patients
Emma Koehorst, IGTP
- RORC and SNAI1 as opposite biomarkers of response to somatostatin receptor ligands in acromegaly
Joan Gil Ortega, IGTP



15.00 - 16.00 SESSION FIVE – Responding to Epidemics in Public Health

Chair: **José A Domínguez**

Strategic Projects

- Nosocomial transmission of SARS-CoV-2 between patients and healthcare personnel during the pandemic
Elisa Martró Català, IGTP
- Tuberculosis and COVID-19 - lessons learned on tuberculosis immunology for COVID-19 response and control (Strategic project; Responding to epidemics in public health)
Irene Latorre Rueda, IGTP

Young investigators' presentations

- Proteomics and immunological studies of circulating extracellular vesicles in COVID-19 patients
Melisa Gualdrón López, ISGLOBAL, IGTP
- Usefulness of a pilot strategy for micro-elimination of HCV in migrants from Pakistan in Catalonia through a community intervention: HepClink study
Anna Not Garí, IGTP/CEEISCAT
- Explaining burnout from isolation in primary care physicians: a mixed-methods study.
Eduard Moreno Gabriel, IDIAPJGOL

16.00 -17.00 SESSION SIX – From Research to Spin-off

Chair: **Raül Zurita**, Head of Innovation and Business Development at the IGTP

- **Julià Blanco**, CEO AlbajunaTherapeutics
- **Pere-Joan Cardona**, CEO Manremyc
- **Simone Calzolari**, CEO ZeClinics
- **Antoni Matilla**, CEO Biointaxis
- **Hernando A del Portillo**, CSO Innovex Therapeutics

17.00 – 17.30 Closing by the Director of IGTP